News for Alexion Pharmaceuticals, Inc. (ALXN)

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atr

On March 31, 2025, Camber Capital Management LLC (Trades, Portfolio) executed a significant reduction in its holdings of Brookdale Senior Living Inc. The firm d

**media[617621]**

PR NewswireTOKYO, May 7, 2025 TOKYO, May 7, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today annou

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing inno

**media[587758,587759]**

EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, at...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines fo

On December 31, 2024, Camber Capital Management LLC (Trades, Portfolio) executed a significant transaction by acquiring 2,722,987 shares of ZimVie Inc at a trad

On December 31, 2024, Camber Capital Management LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 3,197,987 shares of PTC Therapeutics Inc.

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology company has made a remarkable comeback.

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

Labcorp Holdings Inc. (LH) has announced a significant change in its executive leadership team. On November 15, 2024, Glenn Eisenberg, the company's Executive

Certara adds pharmaceutical veteran to board

An increase in the prevalence and misdiagnosis of rare diseases has led to an increase in the sales of orphan drugs....

Claude Nicaise, M.D. appointed Chairman of the Board...

Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE,...

Quince’s transformation is complete with the acquisition of EryDel in October 2023. Check out the reasons why I rate QNCX stock as a Strong Buy.